RR Thenge*

Dr. Rajendra Gode College of Pharmacy, Malkapur, Maharashtra, India

*Corresponding Author: RR Thenge, Dr. Rajendra Gode College of Pharmacy, Malkapur, Maharashtra, India.

Received: February 27, 2023; Published: April 24, 2023

Abstract

Co-crystals are defined as structurally homogeneous/heterogeneous crystalline solids that include drug and coformer in specific stoichiometric proportions. The discrete neutral molecular reactants that make up co-crystals are solids at room temperature. According to this definition of co-crystals, a pharmaceutical co-crystal is a mixture in which one of the co-crystals’ elements serves as an active medicinal ingredient and the other elements serve as coformers. An active drug hydrate is not a co-crystal, as is evident from the statement, but a solid-state drug hydrate is co-crystalline with a coformer to produce a co-crystal [1]. The pharmaceutical sector currently places a lot of attention on co-crystal methods. Pharmaceutical co-crystals can successfully enhance the drug substance’s solubility, dissolving profile, bioavailability and physical stability, in addition to other crucial features such as flowability, chemical stability, compressibility and hygroscopicity [2].

References

1. Torchilin V. “Micellarnano carriers: Pharmaceutical perspectives”. Pharmacy Research 24 (2007): 1-16.
2. Yue X., et al. “Amphiphilic methoxy poly (ethylene glycol)-b-poly (-caprolactone)-b-poly (2-dimethylaminoethyl methacrylate) cationic copolymer nanoparticles as a vector for gene and drug delivery”. Biomacromolecules 11 (2010): 2306-2312.
3. Horst JH., et al. “Discovering new Co-crystals”. Crystal Growth and Design 9 (2009): 1531-1537.
4. Alhalaweh A and Velaga P. “Formation of Co-crystals from stoichiometric solutions of incongruently saturating systems by spray drying”. Crystal Growth and Design8 (2010): 3302-3305.
5. Braga D and Grepioni F. “Reactions between or within molecular crystals”. Chemical International. Edition31 (2004): 4002-4011.
6. Jung M-S., et al. “Bioavailability of indomethacin– saccharin cocrystal”. Journal of Pharmaceutical Pharmacology 62 (2010): 1560-1568.
7. Dai XL., et al. “Improving the membrane permeability of 5-fluorouracil via Cocrystallization”. Crystal Growth and Design8 (2016): 4430-4438.
8. Pagire SK., et al. “Thermodynamic investigation of CarbamazepineSaccharin Co-crystal polymorphs”. Journal of Pharmaceutical Science 106 (2017): 2009-2201.
9. Bethune SJ., et al. “Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility”. Crystal Growth and Design 9 (2009): 3976-3988.
10. Verma S., et al. “Improvement of solubility and bioavailability of aceclofenac using cocrystallization”. Drug Invention Today1 (2019): 59-63.
11. Sanphui P., et al. “Fast dissolving curcumin co-crystals”. Crystal Growth and Design9 (2011): 4135-4145.
12. Newman A and Wenslow R. “Solid form changes during drug development: Good, bad, and ugly case studies”. AAPS Open1 (2016).

Citation

Citation: RR Thenge. “Cocrystals: A New Form of Solid with Improved Physico-chemical Properties". Acta Scientific Pharmaceutical Sciences 7.5 (2023): 20-21.

Copyright

Copyright: © 2023 RR Thenge. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.